RPE65 and retinal disorder: Zimmerman et al. (2019)33 estimated the ICER for voretigene neparvovec (Luxturna) for the treatment for vision loss owing to the ultra‐rare RPE65‐mediated inherited retinal disorders, at $480 100 per QALY gained.